Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction

被引:58
作者
Delgado, DH
Miriuka, SG
Cusimano, RJ
Feindel, C
Rao, V
Ross, HJ
机构
[1] Univ Toronto, Div Cardiol & Transplant, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Div Cardiovasc Surg, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1016/j.healun.2003.09.043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The combined use of basiliximab and cyclosporine in heart transplantation is under investigation. In this study we sought to evaluate the safety and efficacy of basiliximab and delayed initiation of cyclosporine in patients with renal dysfunction undergoing heart transplantation. Methods: Seven patients (Group A) with renal dysfunction (creatinine greater than or equal to200 mumol/liter) received induction therapy with basiliximab. Seven patients (Group B) with renal dysfunction comprised the control group and received induction therapy with rabbit anti-thymocyte serum. Cyclosporine was initiated 5 days post-transplant in Group A and within 5 days post-transplant in Group B. Results: All patients Were alive at the end of the 6-month follow-up. In Group A, mean pre-transplant creatinine was 243 +/- 48 mumol/liter, at 1 week post-transplant was 180 +/- 39 mumol/liter (p = 0.02), at 1 month was 166 +/- 57 mumol/liter (p = 0.619), at 3 months was 182 +/- 25 mumol/liter (p = 0.01) and at 6 months was 179 +/- 45 mumol/liter (p = 0.024). In Group B, mean pre-transplant creatinine was 242 +/- 41 mumol/fiter, at 1 week was 140 +/- 35 mumol/liter (p = 0.0003), at 1 month was 143 38 mumol/liter (p = 0.0005), at 3 months was 138 37 mumol/liter (p = 0.0003) and at 6 months was 154 +/- 30 mumol/liter (p = 0.0006). There were no differences in renal dysfunction between both groups at 1 week (p = 0.069), 1 month (p = 0.39) or 6 months (p = 0.24) post-HT. Fewer episodes of cellular rejection were identified in Group B within the 6-month follow-up period. Conclusions: The use of therapy either with basiliximab or rabbit anti-thymocyte serum in patients with pre-operative renal dysfunction confers renal, protection early and up to 6 months post-transplant. Delayed initiation of cyclosporine might be considered to provide additional renal protection. Copyright (C) 2005 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:166 / 169
页数:4
相关论文
共 6 条
[1]  
BOURGE RC, 1993, J HEART LUNG TRANSPL, V12, P549
[2]   A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation [J].
Carrier, M ;
White, M ;
Perrault, LP ;
Pelletier, GB ;
Pellerin, M ;
Robitaille, D ;
Pelletier, LC .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (12) :1218-1223
[3]  
CONSTANZO MR, 1995, CIRCULATION, V92, P3593
[4]   Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation [J].
Eisen, HJ ;
Hobbs, RE ;
Davis, SF ;
Laufer, G ;
Mancini, DM ;
Renlund, DG ;
Valantine, H ;
Ventura, H ;
Vachiery, JL ;
Bourge, RC ;
Canver, CC ;
Carrier, M ;
Costanzo, MR ;
Copeland, J ;
Dureau, G ;
Frazier, OH ;
Dorent, R ;
Hauptman, PJ ;
Kells, C ;
Masters, R ;
Michaud, JL ;
Paradis, I ;
Smith, A ;
Vanhaecke, J ;
Feutren, G ;
Turkin, D ;
Mellein, B ;
Mueller, EA .
TRANSPLANTATION, 1999, 68 (05) :663-671
[5]  
Ginns LC, 1999, IMMUNOSUPPRESSION TR
[6]   Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].
Kahan, BD ;
Rajagopalan, PR ;
Hall, M .
TRANSPLANTATION, 1999, 67 (02) :276-284